论文部分内容阅读
目的:探讨ERCC1在非小细胞肺癌(NSCLC)组织中的表达及其预后的意义。方法:采用SP法检测129例手术切除NSCLC组织和10例癌旁正常肺组织中ERCC1表达情况,并进行预后随访。结果:在NSCLC组织中ERCC1表达阳性率为48.1%。ERCC1表达与年龄、性别、期别、病理类型均未见相关性,P均>0.05。ERCC1低、高表达者中位生存期为60、29个月,P=0.0001。分层分析发现Ⅰ期ER-CC1阳性表达的预后明显好于ER-CC1阴性表达,中位生存期分别为72和60个月,P=0.0165。而Ⅱ和ⅢA期ERCC1阴性表达较ERCC1阳性预后为好,Ⅱ期中位生存期分别为60和23个月,P=0.0000;ⅢA期中位生存期分别为46和15个月,P=0.0110。结论:NSCLC组织中存在ERCC1表达;ERCC1表达与患者的临床病理特征无明显相关性;ERCC1表达对Ⅰ期和Ⅱ～ⅢA期NSCLC术后生存具有双重效应;ERCC1表达状态是NSCLC患者独立预后因素之一。
Objective: To investigate the expression of ERCC1 in non-small cell lung cancer (NSCLC) and its prognostic significance. Methods: The expression of ERCC1 in 129 cases of NSCLC and 10 cases of adjacent normal lung tissues was detected by SP method and prognosis was followed up. Results: The positive rate of ERCC1 expression in NSCLC tissues was 48.1%. There was no correlation between the expression of ERCC1 and age, sex, stage and pathological type, P> 0.05. The median survival of patients with low and high ERCC1 expression was 60 and 29 months, P = 0.0001. Stratified analysis showed that the prognosis of stage Ⅰ ER-CC1 positive expression was significantly better than that of ER-CC1 negative expression, the median survival was 72 and 60 months, P = 0.0165. The negative expression of ERCC1 in stage Ⅱ and ⅢA was better than that in ERCC1, and the median survival in stage Ⅱ was 60 and 23 months, P = 0.0000 respectively. The median survival of stage ⅢA was 46 and 15 months, P = 0.0110, respectively. Conclusion: ERCC1 expression exists in NSCLC tissues. The expression of ERCC1 has no significant correlation with the clinicopathological features of patients. The expression of ERCC1 has dual effects on the survival of stage Ⅰ and Ⅱ ~ ⅢA NSCLC patients. The expression of ERCC1 is an independent prognostic factor in patients with NSCLC one.